ClinicalTrials.gg
CompletedNCT00762034Updated Dec 21, 2015Results posted

A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer

A Phase 3 interventional study of Pemetrexed and Pemetrexed in Non-small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 67 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-21.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
939
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 223
939 · median 64
Started
2008
with 13 others
Phase 3
44 of 227
4 open now
Registered
78th of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment of the 223 interventional ones that give a count, is one of 14 that started in 2008, is one of 44 in phase 3, and was the 78th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study will compare overall survival in participants with Stage IIIB or IV nonsquamous non-small cell lung cancer.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • You must sign an document for clinical research.
  • You must have Stage IIIB or Stage IV nonsquamous non-small cell lung cancer.
  • You must not have received any prior treatment for your disease.
  • Prior radiation therapy is allowed to \< 25% of the bone marrow; however, prior radiation to the whole pelvis is not allowed. If you have had radiation therapy to the chest, you are not eligible to participate.
  • You must be at least 18 years of age or older.
  • You must have measureable tumor lesions according to the (RECIST) or disease can be evaluated on computed tomography (CT) scan.
  • Your test results assessing the function of blood forming tissue, kidneys and liver must be satisfactory.
  • Women must be sterile, or on and men must be sterile (for example post-vasectomy) or on contraception.

Exclusion criteria

Exclusion Criteria:

  • You cannot have third-space fluid collections (e.g. ascites or pleural effusions that cannot be controlled by drainage or other procedures).
  • You cannot have Non-small Cell Lung Carcinoma (NSCLC) of predominantly squamous cell histology.
  • You cannot have known central nervous system (CNS) disease, other than stable, treated .
  • You cannot have undergone a surgical procedure, open , open pleurodesis, or significant traumatic injury within 28 days of starting the study treatment, or have an anticipated need for major surgery during the study.
  • You cannot have a history of gastrointestinal fistula, perforation, or abscess, inflammatory bowel disease, or diverticulitis.
  • You are currently receiving ongoing treatment with full-dose warfarin or equivalent.
  • You cannot have significant vascular disease, serious cardiac conditions (such as heart attack), stroke or within 6 months of the trial.
  • You cannot have evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).
  • You cannot have inadequately controlled hypertension, or a history of hypertensive crisis or hypertensive encephalopathy.
  • You cannot have a serious, nonhealing wound, active ulcer, or untreated bone fracture.
  • You cannot have another form of cancer, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within the last 5 years.
  • You cannot have received an treatment within 30 days prior to the trial.
  • You cannot have previously received treatment with paclitaxel, carboplatin, pemetrexed, or bevacizumab.
  • You cannot be pregnant or breast-feeding.
  • You cannot have a known sensitivity to any component of paclitaxel, carboplatin, pemetrexed, or bevacizumab.
  • You cannot have a history of hemoptysis (coughing blood) within 3 months prior to the trial.
  • You are unable to stop taking aspirin more than 1.3 grams per day or other nonsteroidal anti-inflammatory drugs (NSAIDs).
  • You are unable or unwilling to take folic acid or vitamin B12 supplementation.
  • You are unable to take .
  • You have any other on-going illnesses including active infections that may not allow you to adhere to the requirements of the trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
939 participants (actual)

Study arms

  • Experimental
    Pem/Carbo/Bev

    Pemetrexed (Pem), carboplatin (Carbo) and bevacizumab (Bev) followed by pemetrexed and bevacizumab

    Drug: Pemetrexed · Drug: Carboplatin · Biological: Bevacizumab

  • Active comparator
    Pac/Carbo/Bev

    Paclitaxel (Pac), carboplatin (Carbo) and bevacizumab (Bev) followed by bevacizumab

    Drug: Paclitaxel · Drug: Carboplatin · Biological: Bevacizumab

Interventions

  • Induction therapy 500 milligram per meter squared (mg/m\^2) intravenously (IV) every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days

    Also known as: Alimta, LY231514

  • Maintenance therapy 500 mg/m\^2 IV every 21 days (with bevacizumab) until progressive disease or treatment discontinuation

    Also known as: Alimta, LY231514

  • Induction therapy 200 mg/m\^2 IV every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days

  • Induction therapy area under the concentration curve (AUC) 6 IV every 21 days for up to 4 cycles of 21 days

  • BiologicalBevacizumab

    Induction therapy 15 milligrams per kilogram (mg/kg) IV every 21 days for up to 4 cycles of 21 days

  • BiologicalBevacizumab

    Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.

    Time frame: Baseline to date of death from any cause (up to 37.06 months)

Secondary outcomes

  1. Percentage of Participants With a Complete Response (CR) and Partial Response (PR) (Overall Response Rate)

    Overall Response Rate (ORR) is the number of participants with a Complete Response (CR) and Partial Response (PR) divided by the total number of randomized participants per arm, then multiplied by 100. Response is based on the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) criteria. Complete Response (CR) was defined as the disappearance of all target lesions. Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions compared to baseline or the complete disappearance of target lesions, with persistence of 1 or more nontarget lesion(s) and no new lesions.

    Time frame: Baseline to measured progressive disease (up to 37.06 months)

  2. Percentage of Participants With a Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate)

    Disease Control Rate (DCR) is the number of participants with a Complete Response (CR), Partial Response (PR), and Stable Disease (SD) divided by the total number of randomized participants per arm, then multiplied by 100. Response is based on the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) criteria. Complete Response (CR) was defined as the disappearance of all target lesions. Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions compared with baseline or the complete disappearance of target lesions, with persistence of 1 or more nontarget lesion(s) and no new lesions. Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions compared with the smallest sum of the longest diameter recorded since the start of treatment or the appearance of 1 or more new lesion(s). Stable Disease (SD) was defined as small changes that did not meet above criteria.

    Time frame: Baseline to measured progressive disease (up to 37.06 months)

  3. Progression Free Survival Time

    Progression free survival (PFS) is defined as the time from date of randomization to the date of objective disease progression or death due to any cause. Participants were censored at date of last PFS assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy, whichever was earlier.

    Time frame: Baseline to measured progressive disease or date of death from any cause (up to 33.54 months)

  4. Time to Progressive Disease

    Time to progressive disease was defined as the time from randomization to the first date of objective disease progression. Participants were censored at date of last PFS assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy, whichever was earlier.

    Time frame: Baseline to measured progressive disease (up to 37.06 months)

  5. Safety and Toxicity Profile of Study Treatments

    Safety and toxicity profile was defined as serious and other non-serious adverse events. A summary of serious and all other non-serious adverse events is located in the Reported Adverse Event module.

    Time frame: Baseline to study endpoint (up to 37.06 months)

  6. Duration of Hospitalizations Per Participant

    Length of hospitalization in participants hospitalized during the study or within 30 days of discontinuation regardless of whether the hospitalization was or was not due to study drug.

    Time frame: Baseline to study endpoint (up to 37.06 months)

  7. Number of Participants Who Received a Transfusion

    Time frame: Baseline to study endpoint (up to 37.06 months)

  8. Number of Participants Receiving Concomitant Medication

    Time frame: Baseline to study endpoint (up to 37.06 months)

  9. Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - General (FACT-G)

    The FACT-G is a validated instrument used to measure quality of life (QOL) in participants with cancer consisting of the 27-item questionnaire and is organized into subscales, each designed to assess a QOL domain: physical well-being (PWB)-7 items; social/family well-being (SWB)-7 items; emotional well-being (EWB)-6 items; functional well-being (FWB)-7 items. Each item uses a 5 point rating scale (0="not at all" and 4=equals "very much"). FACT-G Total is the sum of the scores of all 4 subscales and ranges from 0 to 108. Higher scores indicate better QOL. Least squares mean (LSmean) change is calculated using the linear-mixed model (LMM) analysis controlled for treatment, baseline value, time point and treatment by time point interaction.

    Time frame: Baseline, up to first 10 cycles (4 induction and 6 maintenance cycles, cycle=21 days)

  10. Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - Lung (FACT-L)

    FACT-L is a valid instrument used to measure quality of life (QOL) in participants with cancer consisting of the 27-item FACT-General (G) and 9-item lung cancer subscale (LCS). FACT-G is organized into subscales: physical well-being (PWB)-7 items; social/family well-being (SWB)-7 items; emotional well-being (EWB)-6 items; functional well-being (FWB)-7 items. Each item uses a 5 point rating scale (0="not at all" and 4=equals "very much"). FACT-L Total Score=4 subscales + LCS and ranges from 0 to 144. Trial Outcome Index-Lung (TOI-L)=PWB+FWB+LCS and ranges from 0 to 92. Higher scores indicate better QOL. Least squares mean (LSmean) change is calculated using the linear-mixed model (LMM) analysis controlled for treatment, baseline value, time point and treatment by time point interaction.

    Time frame: Baseline, up to first 10 cycles (4 induction and 6 maintenance cycles, cycle=21 days)

  11. Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group- Neurotoxicity (FACT/GOG-Ntx)

    FACT/GOG-Ntx is a validated instrument used to measure quality of life (QOL) in participants with cancer and neurotoxicity (Ntx) consisting of 27-item FACT-General (G) and 11-item Ntx subscale. FACT-G is organized into domain subscales: physical well-being (PWB)-7 items; social/family well-being (SWB)-7 items; emotional well-being (EWB)-6 items; functional well-being (FWB)-7 items; each uses a 5 point rating scale (0="not at all" and 4=equals "very much"). FACT/GOG-Ntx Total Score=sum 5 subscales and ranges from 0-152. Ntx Trial Outcome Index (TOI-Ntx)=PWB+FWB+NTX and range from 0-100. For all FACT scales, higher scores indicate better QOL. Least squares mean (LSmean) change is calculated using the linear-mixed model (LMM) analysis controlled for treatment, baseline value, time point and treatment by time point interaction.

    Time frame: Baseline, up to first 10 cycles (4 induction and 6 maintenance cycles, cycle=21 days)

  12. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Pemetrexed

    Time frame: Cycle 1 (pre-dose, 0.17, 0.33, 0.58, 0.83, 1, 1.75, 2.5, 4. 6. 8, and 24 hours post-dose)

  13. Pharmacokinetics (PK): Elimination Half-life (t1/2) for Pemetrexed

    Time frame: Cycle 1 (pre-dose, 0.17, 0.33, 0.58, 0.83, 1, 1.75, 2.5, 4. 6. 8, and 24 hours post-dose)

  14. Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Pemetrexed

    Time frame: Cycle 1 (pre-dose, 0.17, 0.33, 0.58, 0.83, 1, 1.75, 2.5, 4. 6. 8, and 24 hours post-dose)

  15. Pharmacokinetics (PK): Pemetrexed Clearance (CL)

    Time frame: Cycle 1 (pre-dose, 0.17, 0.33, 0.58, 0.83, 1, 1.75, 2.5, 4. 6. 8, and 24 hours post-dose)

  16. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Total (Bound and Unbound) Platinum and Unbound Platinum

    Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.

    Time frame: Cycle 1 (pre-dose, 0.25, 0.5, 0.67, 1.42, 2.17, 4, 6, 8, 24, 48, and 72 hours post-dose)

  17. Pharmacokinetics (PK): Elimination Half-life (t1/2) for Total (Bound and Unbound) Platinum and Unbound Platinum

    Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.

    Time frame: Cycle 1 (pre-dose, 0.25, 0.5, 0.67, 1.42, 2.17, 4, 6, 8, 24, 48, and 72 hours post-dose)

  18. Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Total (Bound and Unbound) Platinum and Unbound Platinum

    Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.

    Time frame: Cycle 1 (pre-dose, 0.25, 0.5, 0.67, 1.42, 2.17, 4, 6, 8, 24, 48, and 72 hours post-dose)

  19. Pharmacokinetics (PK): Platinum Clearance (CL) for Total (Bound and Unbound) and Unbound Forms

    Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.

    Time frame: Cycle 1 (pre-dose, 0.25, 0.5, 0.67, 1.42, 2.17, 4, 6, 8, 24, 48, and 72 hours post-dose)

  20. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Bevacizumab

    Time frame: Cycle 1 (pre-dose, 0.75, 1.5, 3, 5, 7, 24, 48, 72, 168, 336, and 503 hours post-dose)

  21. Pharmacokinetics (PK): Elimination Half-life (t1/2) for Bevacizumab

    Time frame: Cycle 1 (pre-dose, 0.75, 1.5, 3, 5, 7, 24, 48, 72, 168, 336, and 503 hours post-dose)

  22. Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) Bevacizumab

    Time frame: Cycle 1 (pre-dose, 0.75, 1.5, 3, 5, 7, 24, 48, 72, 168, 336, and 503 hours post-dose)

  23. Pharmacokinetics (PK): Bevacizumab Clearance (CL)

    Time frame: Cycle 1 (pre-dose, 0.75, 1.5, 3, 5, 7, 24, 48, 72, 168, 336, and 503 hours post-dose)

  24. Translational Research: Number of Participants With Epidermal Growth Factor Receptor (EGFR) Mutations

    Epidermal Growth Factor Receptor (EGFR) mutations were measured by polymerase chain reaction (PCR).

    Time frame: Baseline

  25. Translational Research: Overall Survival (OS) Based on Nuclear Thyroid Transcription Factor-1 (TTF-1) Expression Regardless of Study Treatment

    Nuclear Thyroid Transcription Factor-1 (TTF-1) expression was measured using an Immunohistochemistry (IHC) assay which were scored using a 0 (negative, no staining) to 3+ (brightest staining) scoring system, and H score is a calculated using formula: 1x(percentage of cells stained 1+) + 2x(percentage of cells stained 2+) + 3x(percentage of cells stained 3+). TTF-1 Positive have an H score \>0 and TTF-1 Negative have an H score=0. Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.

    Time frame: Baseline to date of death from any cause (up to 37.06 months)

  26. Translational Research: Overall Survival (OS) Based on Cytoplasmic and Nuclear Thymidylate Synthase (TS) Expression

    Cytoplasmic and nuclear Thymidylate Synthase (TS) expression was measured using an Immunohistochemistry (IHC) assay which were scored using a 0 (negative, no staining) to 3+ (brightest staining) scoring system for cytoplasmic and nuclear staining, and H score was calculated using formula: 1x(percentage of cells stained 1+) + 2x(percentage of cells stained 2+) + 3x(percentage of cells stained 3+). TS Positive have an H score \>0 and TS Negative have an H score=0. Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.

    Time frame: Baseline to date of death from any cause (up to 37.06 months)

  27. Translational Research: Overall Survival (OS) Based on Cytoplasmic and Membrane Folate Receptor Alpha (FR-α) Expression

    Cytoplasmic and membrane Folate Receptor Alpha (FR-α) expression was measured using an Immunohistochemistry (IHC) assay which were scored using a 0 (negative, no staining) to 3+ (brightest staining) scoring system for cytoplasmic or membrane staining, and H score is a calculated using formula: 1x(percentage of cells stained 1+) + 2x(percentage of cells stained 2+) + 3x(percentage of cells stained 3+). FR-α Positive have an H score \>0 and FR-α Negative have an H score=0. Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.

    Time frame: Baseline to date of death from any cause (up to 37.06 months)

07

Results

Posted Nov 28, 2013

Participant flow

Induction Period
Participant flow — Induction Period
MilestonePem/Carbo/BevPac/Carbo/Bev
Started472467
Received at least 1 dose of study drug442443
Completed294298
Not completed178169
Withdrew: Protocol violation12
Withdrew: Entry criterion not met1211
Withdrew: Adverse event2738
Withdrew: Lost to follow-up11
Withdrew: Progressive disease7355
Withdrew: Physician decision2120
Withdrew: Withdrawal by subject1519
Withdrew: Deaths not due to study disease1914
Withdrew: Deaths due to study disease99
Maintenance Period
Participant flow — Maintenance Period
MilestonePem/Carbo/BevPac/Carbo/Bev
Started294298
Received at least 1 dose of study drug294298
Completed00
Not completed294298
Withdrew: Protocol violation13
Withdrew: Entry criterion not met02
Withdrew: Adverse event4226
Withdrew: Progressive disease186224
Withdrew: Physician decision2520
Withdrew: Withdrawal by subject3414
Withdrew: Death not due to study disease25
Withdrew: Death due to study disease33
Withdrew: Other11

Outcome measures

PrimaryOverall Survival

Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.

Time frame:
Baseline to date of death from any cause (up to 37.06 months)
Reported as:
Median · months
Overall Survival
monthsPem/Carbo/BevPac/Carbo/Bev
Overall Survival12.55 (11.30 to 14.03)13.40 (11.86 to 14.91)
Statistical analysis
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Log Rank · p = 0.94896 · Hazard ratio (hr): 1.00 · 95% CI 0.86 to 1.16
SecondaryPercentage of Participants With a Complete Response (CR) and Partial Response (PR) (Overall Response Rate)

Overall Response Rate (ORR) is the number of participants with a Complete Response (CR) and Partial Response (PR) divided by the total number of randomized participants per arm, then multiplied by 100. Response is based on the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) criteria. Complete Response (CR) was defined as the disappearance of all target lesions. Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions compared to baseline or the complete disappearance of target lesions, with persistence of 1 or more nontarget lesion(s) and no new lesions.

Time frame:
Baseline to measured progressive disease (up to 37.06 months)
Reported as:
Number · percentage of participants
Percentage of Participants With a Complete Response (CR) and Partial Response (PR) (Overall Response Rate)
percentage of participantsPem/Carbo/BevPac/Carbo/Bev
Percentage of Participants With a Complete Response (CR) and Partial Response (PR) (Overall Response Rate)34.1 (29.8 to 38.6)33.0 (28.7 to 37.4)
Statistical analysis
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Fisher Exact · p = 0.72997
SecondaryPercentage of Participants With a Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate)

Disease Control Rate (DCR) is the number of participants with a Complete Response (CR), Partial Response (PR), and Stable Disease (SD) divided by the total number of randomized participants per arm, then multiplied by 100. Response is based on the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) criteria. Complete Response (CR) was defined as the disappearance of all target lesions. Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions compared with baseline or the complete disappearance of target lesions, with persistence of 1 or more nontarget lesion(s) and no new lesions. Progressive Disease (PD) was defined as at least 20% increase in sum of longest diameter of target lesions compared with the smallest sum of the longest diameter recorded since the start of treatment or the appearance of 1 or more new lesion(s). Stable Disease (SD) was defined as small changes that did not meet above criteria.

Time frame:
Baseline to measured progressive disease (up to 37.06 months)
Reported as:
Number · percentage of participants
Percentage of Participants With a Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate)
percentage of participantsPem/Carbo/BevPac/Carbo/Bev
Percentage of Participants With a Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate)65.9 (61.4 to 70.2)69.8 (65.4 to 73.9)
Statistical analysis
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Fisher Exact · p = 0.20892
SecondaryProgression Free Survival Time

Progression free survival (PFS) is defined as the time from date of randomization to the date of objective disease progression or death due to any cause. Participants were censored at date of last PFS assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy, whichever was earlier.

Time frame:
Baseline to measured progressive disease or date of death from any cause (up to 33.54 months)
Reported as:
Median · months
Progression Free Survival Time
monthsPem/Carbo/BevPac/Carbo/Bev
Progression Free Survival Time6.04 (5.55 to 6.87)5.55 (5.39 to 5.98)
Statistical analysis
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Log Rank · p = 0.01206 · Hazard ratio (hr): 0.83 · 95% CI 0.71 to 0.96
SecondaryTime to Progressive Disease

Time to progressive disease was defined as the time from randomization to the first date of objective disease progression. Participants were censored at date of last PFS assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy, whichever was earlier.

Time frame:
Baseline to measured progressive disease (up to 37.06 months)
Reported as:
Median · months
Time to Progressive Disease
monthsPem/Carbo/BevPac/Carbo/Bev
Time to Progressive Disease7.03 (6.24 to 8.05)6.04 (5.58 to 6.87)
Statistical analysis
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Log Rank · p = 0.006 · Hazard ratio (hr): 0.79 · 95% CI 0.67 to 0.94
SecondarySafety and Toxicity Profile of Study Treatments

Safety and toxicity profile was defined as serious and other non-serious adverse events. A summary of serious and all other non-serious adverse events is located in the Reported Adverse Event module.

Time frame:
Baseline to study endpoint (up to 37.06 months)
Reported as:
Number · participants
Safety and Toxicity Profile of Study Treatments
participantsPem/Carbo/Bev; Induction PhasePem/Carbo/Bev; Maintenance PhasePac/Carbo/Bev; Induction PhasePac/Carbo/Bev; Maintenance Phase
Serious Adverse Events (SAEs)1118312368
Other Adverse Events (AEs)432288431296
SecondaryDuration of Hospitalizations Per Participant

Length of hospitalization in participants hospitalized during the study or within 30 days of discontinuation regardless of whether the hospitalization was or was not due to study drug.

Time frame:
Baseline to study endpoint (up to 37.06 months)
Reported as:
Mean · days
Duration of Hospitalizations Per Participant
daysPem/Carbo/BevPac/Carbo/Bev
Duration of Hospitalizations Per Participant9.4 ± 9.88.0 ± 6.7
SecondaryNumber of Participants Who Received a Transfusion
Time frame:
Baseline to study endpoint (up to 37.06 months)
Reported as:
Number · participants
Number of Participants Who Received a Transfusion
participantsPem/Carbo/BevPac/Carbo/Bev
Number of Participants Who Received a Transfusion11644
SecondaryNumber of Participants Receiving Concomitant Medication
Time frame:
Baseline to study endpoint (up to 37.06 months)
Reported as:
Number · participants
Number of Participants Receiving Concomitant Medication
participantsPem/Carbo/BevPac/Carbo/Bev
Number of Participants Receiving Concomitant Medication406421
SecondaryChange From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - General (FACT-G)

The FACT-G is a validated instrument used to measure quality of life (QOL) in participants with cancer consisting of the 27-item questionnaire and is organized into subscales, each designed to assess a QOL domain: physical well-being (PWB)-7 items; social/family well-being (SWB)-7 items; emotional well-being (EWB)-6 items; functional well-being (FWB)-7 items. Each item uses a 5 point rating scale (0="not at all" and 4=equals "very much"). FACT-G Total is the sum of the scores of all 4 subscales and ranges from 0 to 108. Higher scores indicate better QOL. Least squares mean (LSmean) change is calculated using the linear-mixed model (LMM) analysis controlled for treatment, baseline value, time point and treatment by time point interaction.

Time frame:
Baseline, up to first 10 cycles (4 induction and 6 maintenance cycles, cycle=21 days)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - General (FACT-G)
units on a scalePem/Carbo/BevPac/Carbo/Bev
Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - General (FACT-G)0.51 ± 0.540.18 ± 0.54
Statistical analysis
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Mixed Models Analysis · p = 0.667 (Mixed Model Analysis has treatment, baseline, time point, and treatment by timepoint interaction as fixed effects.)
SecondaryChange From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - Lung (FACT-L)

FACT-L is a valid instrument used to measure quality of life (QOL) in participants with cancer consisting of the 27-item FACT-General (G) and 9-item lung cancer subscale (LCS). FACT-G is organized into subscales: physical well-being (PWB)-7 items; social/family well-being (SWB)-7 items; emotional well-being (EWB)-6 items; functional well-being (FWB)-7 items. Each item uses a 5 point rating scale (0="not at all" and 4=equals "very much"). FACT-L Total Score=4 subscales + LCS and ranges from 0 to 144. Trial Outcome Index-Lung (TOI-L)=PWB+FWB+LCS and ranges from 0 to 92. Higher scores indicate better QOL. Least squares mean (LSmean) change is calculated using the linear-mixed model (LMM) analysis controlled for treatment, baseline value, time point and treatment by time point interaction.

Time frame:
Baseline, up to first 10 cycles (4 induction and 6 maintenance cycles, cycle=21 days)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - Lung (FACT-L)
units on a scalePem/Carbo/BevPac/Carbo/Bev
FACT-L Total Score (n=397, 392)1.88 ± 0.651.66 ± 0.66
Trial Outcome Index-Lung (TOI-L) (n=396, 394)-0.38 ± 0.50-0.40 ± 0.50
Statistical analysis
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Mixed Models Analysis · p = 0.815 (p-value for FACT-L Total; Mixed Model Analysis has treatment, baseline, time point, and treatment by timepoint interaction as fixed effects.)
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Mixed Models Analysis · p = 0.978 (p-value for FACT-L TOI; Mixed Model Analysis has treatment, baseline, time point, and treatment by timepoint interaction as fixed effects.)
SecondaryChange From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group- Neurotoxicity (FACT/GOG-Ntx)

FACT/GOG-Ntx is a validated instrument used to measure quality of life (QOL) in participants with cancer and neurotoxicity (Ntx) consisting of 27-item FACT-General (G) and 11-item Ntx subscale. FACT-G is organized into domain subscales: physical well-being (PWB)-7 items; social/family well-being (SWB)-7 items; emotional well-being (EWB)-6 items; functional well-being (FWB)-7 items; each uses a 5 point rating scale (0="not at all" and 4=equals "very much"). FACT/GOG-Ntx Total Score=sum 5 subscales and ranges from 0-152. Ntx Trial Outcome Index (TOI-Ntx)=PWB+FWB+NTX and range from 0-100. For all FACT scales, higher scores indicate better QOL. Least squares mean (LSmean) change is calculated using the linear-mixed model (LMM) analysis controlled for treatment, baseline value, time point and treatment by time point interaction.

Time frame:
Baseline, up to first 10 cycles (4 induction and 6 maintenance cycles, cycle=21 days)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group- Neurotoxicity (FACT/GOG-Ntx)
units on a scalePem/Carbo/BevPac/Carbo/Bev
FACT/GOG-Ntx Total Score (n=393, 389)-0.60 ± 0.70-5.48 ± 0.70
Ntx Trial Outcome Index (TOI-Ntx)(n=393, 390)-2.79 ± 0.55-7.60 ± 0.55
Statistical analysis
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Mixed Models Analysis · p = <0.001 (p-value for FACT/GOG-Ntx Total; Mixed Model Analysis has treatment, baseline, time point, and treatment by timepoint interaction as fixed effects.)
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Mixed Models Analysis · p = <0.001 (p-value for FACT/GOG-Ntx TOI; Mixed Model Analysis has treatment, baseline, time point, and treatment by timepoint interaction as fixed effects.)
SecondaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Pemetrexed
Time frame:
Cycle 1 (pre-dose, 0.17, 0.33, 0.58, 0.83, 1, 1.75, 2.5, 4. 6. 8, and 24 hours post-dose)
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Pemetrexed
micrograms per milliliter (μg/mL)Pem/Carbo/Bev
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Pemetrexed122 ± 20
SecondaryPharmacokinetics (PK): Elimination Half-life (t1/2) for Pemetrexed
Time frame:
Cycle 1 (pre-dose, 0.17, 0.33, 0.58, 0.83, 1, 1.75, 2.5, 4. 6. 8, and 24 hours post-dose)
Reported as:
Geometric mean · hours (hr)
Pharmacokinetics (PK): Elimination Half-life (t1/2) for Pemetrexed
hours (hr)Pem/Carbo/Bev
Pharmacokinetics (PK): Elimination Half-life (t1/2) for Pemetrexed2.88 ± 13
SecondaryPharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Pemetrexed
Time frame:
Cycle 1 (pre-dose, 0.17, 0.33, 0.58, 0.83, 1, 1.75, 2.5, 4. 6. 8, and 24 hours post-dose)
Reported as:
Geometric mean · microgram*hour per milliliter (μg•hr/mL)
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Pemetrexed
microgram*hour per milliliter (μg•hr/mL)Pem/Carbo/Bev
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Pemetrexed203 ± 23
SecondaryPharmacokinetics (PK): Pemetrexed Clearance (CL)
Time frame:
Cycle 1 (pre-dose, 0.17, 0.33, 0.58, 0.83, 1, 1.75, 2.5, 4. 6. 8, and 24 hours post-dose)
Reported as:
Geometric mean · milliliters per minute (mL/min)
Pharmacokinetics (PK): Pemetrexed Clearance (CL)
milliliters per minute (mL/min)Pem/Carbo/Bev
Pharmacokinetics (PK): Pemetrexed Clearance (CL)72.1 ± 25
SecondaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Total (Bound and Unbound) Platinum and Unbound Platinum

Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.

Time frame:
Cycle 1 (pre-dose, 0.25, 0.5, 0.67, 1.42, 2.17, 4, 6, 8, 24, 48, and 72 hours post-dose)
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Total (Bound and Unbound) Platinum and Unbound Platinum
micrograms per milliliter (μg/mL)Pem/Carbo/BevPac/Carbo/Bev
Total (Bound and Unbound)18.4 ± 2417.8 ± 33
Unbound (n=18, 15)21.1 ± 3117.1 ± 34
SecondaryPharmacokinetics (PK): Elimination Half-life (t1/2) for Total (Bound and Unbound) Platinum and Unbound Platinum

Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.

Time frame:
Cycle 1 (pre-dose, 0.25, 0.5, 0.67, 1.42, 2.17, 4, 6, 8, 24, 48, and 72 hours post-dose)
Reported as:
Geometric mean · hours (hr)
Pharmacokinetics (PK): Elimination Half-life (t1/2) for Total (Bound and Unbound) Platinum and Unbound Platinum
hours (hr)Pem/Carbo/BevPac/Carbo/Bev
Total (Bound and Unbound)65.6 ± 6986.4 ± 21
Unbound (n=17, 13)2.03 ± 151.95 ± 21
SecondaryPharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Total (Bound and Unbound) Platinum and Unbound Platinum

Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.

Time frame:
Cycle 1 (pre-dose, 0.25, 0.5, 0.67, 1.42, 2.17, 4, 6, 8, 24, 48, and 72 hours post-dose)
Reported as:
Geometric mean · microgram*hour per milliliter (μg•hr/mL)
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Total (Bound and Unbound) Platinum and Unbound Platinum
microgram*hour per milliliter (μg•hr/mL)Pem/Carbo/BevPac/Carbo/Bev
Total (Bound and Unbound)160 ± 32182 ± 24
Unbound (n=17, 13)55.7 ± 3362.9 ± 34
SecondaryPharmacokinetics (PK): Platinum Clearance (CL) for Total (Bound and Unbound) and Unbound Forms

Platinum is a metabolite of Carboplatin (Carbo) and is found in the blood as both a bound and unbound form.

Time frame:
Cycle 1 (pre-dose, 0.25, 0.5, 0.67, 1.42, 2.17, 4, 6, 8, 24, 48, and 72 hours post-dose)
Reported as:
Geometric mean · liters per hour (L/hr)
Pharmacokinetics (PK): Platinum Clearance (CL) for Total (Bound and Unbound) and Unbound Forms
liters per hour (L/hr)Pem/Carbo/BevPac/Carbo/Bev
Total (Bound and Unbound)2.02 ± 391.87 ± 28
Unbound (n=17, 13)5.81 ± 355.36 ± 47
SecondaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Bevacizumab
Time frame:
Cycle 1 (pre-dose, 0.75, 1.5, 3, 5, 7, 24, 48, 72, 168, 336, and 503 hours post-dose)
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Bevacizumab
micrograms per milliliter (μg/mL)Pem/Carbo/BevPac/Carbo/Bev
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Bevacizumab276 ± 18302 ± 20
SecondaryPharmacokinetics (PK): Elimination Half-life (t1/2) for Bevacizumab
Time frame:
Cycle 1 (pre-dose, 0.75, 1.5, 3, 5, 7, 24, 48, 72, 168, 336, and 503 hours post-dose)
Reported as:
Geometric mean · days
Pharmacokinetics (PK): Elimination Half-life (t1/2) for Bevacizumab
daysPem/Carbo/BevPac/Carbo/Bev
Pharmacokinetics (PK): Elimination Half-life (t1/2) for Bevacizumab14.8 ± 3612.8 ± 46
SecondaryPharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) Bevacizumab
Time frame:
Cycle 1 (pre-dose, 0.75, 1.5, 3, 5, 7, 24, 48, 72, 168, 336, and 503 hours post-dose)
Reported as:
Geometric mean · microgram*day per milliliter (μg•day/mL)
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) Bevacizumab
microgram*day per milliliter (μg•day/mL)Pem/Carbo/BevPac/Carbo/Bev
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) Bevacizumab3070 ± 293160 ± 33
SecondaryPharmacokinetics (PK): Bevacizumab Clearance (CL)
Time frame:
Cycle 1 (pre-dose, 0.75, 1.5, 3, 5, 7, 24, 48, 72, 168, 336, and 503 hours post-dose)
Reported as:
Geometric mean · liters per day (L/day)
Pharmacokinetics (PK): Bevacizumab Clearance (CL)
liters per day (L/day)Pem/Carbo/BevPac/Carbo/Bev
Pharmacokinetics (PK): Bevacizumab Clearance (CL)0.341 ± 310.376 ± 38
SecondaryTranslational Research: Number of Participants With Epidermal Growth Factor Receptor (EGFR) Mutations

Epidermal Growth Factor Receptor (EGFR) mutations were measured by polymerase chain reaction (PCR).

Time frame:
Baseline
Reported as:
Number · participants
Translational Research: Number of Participants With Epidermal Growth Factor Receptor (EGFR) Mutations
participantsPem or Pac Plus Carbo/Bev
EGFR mutation positive11
EGFR mutation negative121
SecondaryTranslational Research: Overall Survival (OS) Based on Nuclear Thyroid Transcription Factor-1 (TTF-1) Expression Regardless of Study Treatment

Nuclear Thyroid Transcription Factor-1 (TTF-1) expression was measured using an Immunohistochemistry (IHC) assay which were scored using a 0 (negative, no staining) to 3+ (brightest staining) scoring system, and H score is a calculated using formula: 1x(percentage of cells stained 1+) + 2x(percentage of cells stained 2+) + 3x(percentage of cells stained 3+). TTF-1 Positive have an H score \>0 and TTF-1 Negative have an H score=0. Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.

Time frame:
Baseline to date of death from any cause (up to 37.06 months)
Reported as:
Median · months
Translational Research: Overall Survival (OS) Based on Nuclear Thyroid Transcription Factor-1 (TTF-1) Expression Regardless of Study Treatment
monthsTTF-1 Positive (H Score > 0)TTF-1 Negative (H Score = 0)
Translational Research: Overall Survival (OS) Based on Nuclear Thyroid Transcription Factor-1 (TTF-1) Expression Regardless of Study Treatment14.9 (12.8 to 17.6)8.7 (6.4 to 10.5)
Statistical analysis
  • TTF-1 Positive (H Score > 0) vs TTF-1 Negative (H Score = 0) · Regression, Cox · p = <0.001 (p-value was not adjusted for multiple comparisons.) · Hazard ratio (hr): 0.480 · 95% CI 0.338 to 0.681
SecondaryTranslational Research: Overall Survival (OS) Based on Cytoplasmic and Nuclear Thymidylate Synthase (TS) Expression

Cytoplasmic and nuclear Thymidylate Synthase (TS) expression was measured using an Immunohistochemistry (IHC) assay which were scored using a 0 (negative, no staining) to 3+ (brightest staining) scoring system for cytoplasmic and nuclear staining, and H score was calculated using formula: 1x(percentage of cells stained 1+) + 2x(percentage of cells stained 2+) + 3x(percentage of cells stained 3+). TS Positive have an H score \>0 and TS Negative have an H score=0. Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.

Time frame:
Baseline to date of death from any cause (up to 37.06 months)
Reported as:
Median · months
Translational Research: Overall Survival (OS) Based on Cytoplasmic and Nuclear Thymidylate Synthase (TS) Expression
monthsPem/Carbo/BevPac/Carbo/Bev
TS Cytoplasm Positive (H score > 0; n=90, 83)12.9 (10.8 to 16.9)12.4 (10.9 to 15.5)
TS Cytoplasm Negative (H score = 0; n=10, 6)18.2 (12.5 to NA)11.6 (9.1 to 14.7)
TS Nucleus Positive (H score > 0; n=68, 51)12.7 (9.7 to 15.4)12.4 (8.4 to 15.5)
TS Nucleus Negative (H score = 0; n=32, 38)19.2 (12.5 to 24.1)12.4 (10.1 to 17.1)
Statistical analysis
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Regression, Cox · p = 0.673 (p-value is for TS Cytoplasm Positive (H score \> 0) comparing treatment arms and was not adjusted for multiple comparisons.) · Hazard ratio (hr): 0.927 · 95% CI 0.654 to 1.316
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Regression, Cox · p = 0.287 (p-value is for TS Cytoplasm Negative (H score = 0) comparing treatment arms and was not adjusted for multiple comparisons.) · Hazard ratio (hr): 0.521 · 95% CI 0.157 to 1.729
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Regression, Cox · p = 0.2 (p-value is for TS Nucleus Positive (H score \> 0) comparing treatment arms and was not adjusted for multiple comparisons.) · Hazard ratio (hr): 0.759 · 95% CI 0.498 to 1.157
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Regression, Cox · p = 0.915 (p-value is for TS Nucleus Negative (H score = 0) comparing treatment arms and was not adjusted for multiple comparisons.) · Hazard ratio (hr): 0.969 · 95% CI 0.540 to 1.738
SecondaryTranslational Research: Overall Survival (OS) Based on Cytoplasmic and Membrane Folate Receptor Alpha (FR-α) Expression

Cytoplasmic and membrane Folate Receptor Alpha (FR-α) expression was measured using an Immunohistochemistry (IHC) assay which were scored using a 0 (negative, no staining) to 3+ (brightest staining) scoring system for cytoplasmic or membrane staining, and H score is a calculated using formula: 1x(percentage of cells stained 1+) + 2x(percentage of cells stained 2+) + 3x(percentage of cells stained 3+). FR-α Positive have an H score \>0 and FR-α Negative have an H score=0. Overall survival (OS) is the duration from date of randomization to date of death from any cause. Participants were censored at the date they were last known to be alive.

Time frame:
Baseline to date of death from any cause (up to 37.06 months)
Reported as:
Median · months
Translational Research: Overall Survival (OS) Based on Cytoplasmic and Membrane Folate Receptor Alpha (FR-α) Expression
monthsPem/Carbo/BevPac/Carbo/Bev
FR-α Cytoplasm Positive (H score > 0; n=64, 53)14.4 (11.4 to 22.2)14.3 (11.2 to 18.2)
FR-α Cytoplasm Negative (H score = 0; n=34, 29)12.0 (9.6 to 16.9)11.2 (5.7 to 14.4)
FR-α Membrane Positive (H score > 0; n=39, 22)19.2 (10.5 to 30.8)15.5 (11.2 to NA)
FR-α Membrane Negative (H score = 0; n=59, 60)12.9 (9.6 to 16.7)11.3 (8.8 to 14.7)
Statistical analysis
  • Pac/Carbo/Bev · Regression, Cox · p = 0.891 (p-value for FR-α Cytoplasm Positive (H score \> 0) comparing treatment arms and was not adjusted for multiple comparisons.) · Hazard ratio (hr): 0.970 · 95% CI 0.622 to 1.511
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Regression, Cox · p = 0.060 (p-value for FR-α Cytoplasm Negative (H score = 0) comparing treatment arms and was not adjusted for multiple comparisons.) · Hazard ratio (hr): 0.592 · 95% CI 0.342 to 1.023
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Regression, Cox · p = 0.905 (p-value for FR-α Membrane Positive (H score \> 0) comparing treatment arms and was not adjusted for multiple comparisons.) · Hazard ratio (hr): 0.960 · 95% CI 0.490 to 1.880
  • Pem/Carbo/Bev vs Pac/Carbo/Bev · Regression, Cox · p = 0.455 (p-value for FR-α Membrane Negative (H score = 0) comparing treatment arms and was not adjusted for multiple comparisons.) · Hazard ratio (hr): 0.859 · 95% CI 0.575 to 1.281

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pem/Carbo/Bev—188/442 (42.5%)430/442 (97.3%)
Pac/Carbo/Bev—181/443 (40.9%)433/443 (97.7%)
Most frequent serious events
Showing 10 of 256
Most frequent serious events
EventPem/Carbo/BevPac/Carbo/Bev
PneumoniaInfections and infestations28/44227/443
DehydrationMetabolism and nutrition disorders20/44221/443
AnaemiaBlood and lymphatic system disorders18/4425/443
Deep vein thrombosisVascular disorders5/44214/443
VomitingGastrointestinal disorders13/44211/443
Febrile neutropeniaBlood and lymphatic system disorders6/44213/443
ThrombocytopeniaBlood and lymphatic system disorders12/4423/443
Respiratory failureRespiratory, thoracic and mediastinal disorders11/4424/443
NauseaGastrointestinal disorders9/44211/443
NeutropeniaBlood and lymphatic system disorders10/4429/443
Most frequent other events
Showing 10 of 61
Most frequent other events
EventPem/Carbo/BevPac/Carbo/Bev
FatigueGeneral disorders268/442257/443
NauseaGastrointestinal disorders236/442223/443
NeutropeniaBlood and lymphatic system disorders170/442219/443
AlopeciaSkin and subcutaneous tissue disorders34/442193/443
ConstipationGastrointestinal disorders181/442166/443
AnaemiaBlood and lymphatic system disorders177/442136/443
ThrombocytopeniaBlood and lymphatic system disorders159/442105/443
Decreased appetiteMetabolism and nutrition disorders133/442145/443
Neuropathy peripheralNervous system disorders42/442145/443
DiarrhoeaGastrointestinal disorders100/442118/443

Baseline characteristics

All randomized participants.

Age, Customized
Age, Customized(participants)Pem/Carbo/BevPac/Carbo/BevTotal
<=65 years249236485
>65 years223231454
Sex: Female, Male
Sex: Female, Male(Participants)Pem/Carbo/BevPac/Carbo/BevTotal
Female221218439
Male251249500
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pem/Carbo/BevPac/Carbo/BevTotal
Caucasian409396805
Black or African American425294
Asian151429
American Indian or Alaska Native112
Multiple race/ethnicities235
Information not provided314
Region of Enrollment
Region of Enrollment(participants)Pem/Carbo/BevPac/Carbo/BevTotal
United States472467939
Previously Treated Brain Metastasis
Previously Treated Brain Metastasis(participants)Pem/Carbo/BevPac/Carbo/BevTotal
Yes5252104
No420415835
Histological Subtype
Histological Subtype(participants)Pem/Carbo/BevPac/Carbo/BevTotal
Adenocarcinoma, Lung367360727
Bronchioalveolar Carcinoma437
Large Cell Lung Carcinoma81523
NSCLC Not Otherwise Specified473986
NSCLC Poorly Differentiated394786
Predominantly Adenocarcinoma729
Unknown011
Histological Category for Subgroup Analyses
Histological Category for Subgroup Analyses(participants)Pem/Carbo/BevPac/Carbo/BevTotal
Adenocarcinoma378365743
Large Cell Carcinoma81523
Other or Indeterminant8686172
Unknown011
08

Study locations

67 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fayetteville, Arkansas 72703, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jonesboro, Arkansas 72401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Alhambra, California 91801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bakersfield, California 93309, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Duarte, California 91010, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fountain Valley, California 92708, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fullerton, California 92835, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Verne, California 91750, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Long Beach, California 90813, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Los Angeles, California 90095, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Northridge, California 91325, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rancho Mirage, California 92270, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Redondo Beach, California 90277, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santa Barbara, California 93105, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santa Maria, California 93454, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santa Rosa, California 95403, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Grand Junction, Colorado 81501, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Boca Raton, Florida 33486, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Coral Springs, Florida 33065, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Myers, Florida 33916, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jacksonville, Florida 32256, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lake Worth, Florida 33467, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Melbourne, Florida 32901, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orlando, Florida 32804, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pembroke Pines, Florida 33028, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Port St Lucie, Florida 34952, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stuart, Florida 34994, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Athens, Georgia 30607, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Augusta, Georgia 30901, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Gordon, Georgia 30905, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chicago, Illinois 60612, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gurnee, Illinois 60031, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Skokie, Illinois 60077, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Albany, Indiana 47150, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wichita, Kansas 67214, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Louisville, Kentucky 40205, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baton Rouge, Louisiana 70809, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baltimore, Maryland 21237, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bethesda, Maryland 20817, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chevy Chase, Maryland 20815, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frederick, Maryland 21701, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rockville, Maryland 20850, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Boston, Massachusetts 02115, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Framingham, Massachusetts 01701, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lambertville, Michigan 48144, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Duluth, Minnesota 55805, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Minneapolis, Minnesota 55417, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis, Missouri 63110, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Reno, Nevada 89502, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bronx, New York 10467, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stony Brook, New York 11794, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chapel Hill, North Carolina 27514, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cincinnati, Ohio 45242, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Columbus, Ohio 43219, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oklahoma City, Oklahoma 73120, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tulsa, Oklahoma 74136, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kittanning, Pennsylvania 16201, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Willow Grove, Pennsylvania 19090, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Columbia, South Carolina 29210, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Knoxville, Tennessee 37920, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee 38120, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78229, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    The Woodlands, Texas 77380, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Abingdon, Virginia 24211, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Richmond, Virginia 23230, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tacoma, Washington 98405, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Spigel DR, Patel JD, Reynolds CH, Garon EB, Hermann RC, Govindan R, Olsen MR, Winfree KB, Chen J, Liu J, Guba SC, Socinski MA, Bonomi P. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Feb;10(2):353-9. doi: 10.1097/JTO.0000000000000277. PubMed 25611228 ↗
  • Reynolds CH, Patel JD, Garon EB, Olsen MR, Bonomi P, Govindan R, Pennella EJ, Liu J, Guba SC, Li S, Spigel DR, Hermann RC, Socinski MA, Obasaju CK. Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015 May;16(3):200-8. doi: 10.1016/j.cllc.2014.11.004. Epub 2014 Nov 18. PubMed 25516338 ↗
  • Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Dec 1;31(34):4349-57. doi: 10.1200/JCO.2012.47.9626. Epub 2013 Oct 21. PubMed 24145346 ↗
  • Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S, Obasaju C, Pennella EJ, Girvan AC, Guba SC. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2009 Jul;10(4):252-6. doi: 10.3816/CLC.2009.n.035. PubMed 19632943 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Apr 2012 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2008
First posted
Sep 30, 2008
Start
Dec 2008
Primary completionActual
Apr 2012
CompletionActual
Dec 2014
Results first posted
Nov 28, 2013
Last update
Dec 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00762034
Responsible party
Sponsor
First posted
Sep 30, 2008
Start date
Dec 2008
Primary completion
Apr 2012
Completion
Dec 2014
Results posted
Nov 28, 2013
Last update
Dec 21, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMC - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion